We are very excited to welcome People Science to the FORM Life community and we are inspired by its founders, Noah and Belinda, who were introduced to us late last year under the assumption there was a perfect fit. We quickly agreed and we are proud to support their ambitious venture. Their vision is one we believe in, where individuals are empowered to ask, “which alternative medicines work best for me?” With years of entrepreneurial experience building digital clinical research tools for pharma at Science37, we believe Noah and Belinda are the ones to build this. Their second act now accumulates all of their knowledge and experience into People Science, a company that brings the same scientific rigor to people and organizations studying the health impact of preventive interventions.
More than ever, people around the world need new ideas and solutions that disrupt our approach to healthcare. But how do we know which interventions are actually effective? This is where People Science and direct-to-consumer clinical trials come in.
How do they do it? People Science is building a new clinical research infrastructure for alternative medicines that connects people, doctors, and scientists through its technology platform. Their modular software technology combines a consumer-facing mobile app with a rigorous high-quality clinical research platform. Consumers can use this tool to help understand which alternative medicines work best for them, while companies and other researchers can engage with People Science to test their ideas and products.
We see many advantages to this approach. People Science now unlocks the ability to examine an individual's response to an intervention. We know this is important because what works for one person may not work for another and by studying an individual's response to an intervention, clinical trials conducted by People Science can provide valuable information about the effectiveness of an intervention for that specific person. Another advantage of direct-to-consumer clinical trials is that they can be completed in a relatively short period of time and with a limited budget, making them accessible to a wide range of individuals and organizations. These trials allow individuals to take control of their own health and have a direct say in the research that affects them.
We are excited to join People Science on this journey, especially as they prepare for their 2023 public launch. We joined an incredible syndicate for this seed round, including lead investor Acre Venture Partners as well as Bluestein Ventures and THIA Ventures. Our growing community is poised to transform healthcare and we welcome the People Science team to our FORM Life family.